Disc Medicine (IRON) EPS (Weighted Average and Diluted) (2021 - 2026)
Disc Medicine (IRON) reported EPS (Weighted Average and Diluted) of -$1.65 for Q1 2026, down 61.76% year-over-year from -$4.32 in Q1 2025, and down 1.85% quarter-over-quarter from -$1.62 in Q4 2025.
Disc Medicine (IRON) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Disc Medicine (IRON) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.65 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.65, down 61.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.62 (down 68.88% YoY), and the FY2025 annual result was -$6.01, down 51.77% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$1.65 in Q1 2026 per IRON's latest filing, from -$1.62 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.58 in Q3 2023 and troughed at -$16.82 in Q3 2022.
- A 5-year average of -$3.53 and a median of -$1.2 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) sank 3811.63% in 2022, then soared 96.55% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$7.32 in 2022, then surged by 86.75% to -$0.97 in 2023, then dropped by 1.03% to -$0.98 in 2024, then tumbled by 65.31% to -$1.62 in 2025, then retreated by 1.85% to -$1.65 in 2026.
- Business Quant data shows IRON's EPS (Weighted Average and Diluted) at -$1.65 in Q1 2026, -$1.62 in Q4 2025, and -$1.77 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Disc Medicine | 2.73 Bn | 2.00 Bn | - | -1.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.65 |
| Dec 31, 2025 | -1.62 |
| Sep 30, 2025 | -1.77 |
| Jun 30, 2025 | -1.58 |
| Mar 31, 2025 | -1.02 |
| Dec 31, 2024 | -0.98 |
| Sep 30, 2024 | -0.89 |
| Jun 30, 2024 | -1.03 |
| Mar 31, 2024 | -1.09 |
| Dec 31, 2023 | -0.97 |
| Sep 30, 2023 | -0.58 |
| Jun 30, 2023 | -0.74 |
| Mar 31, 2023 | -1.20 |
| Dec 31, 2022 | -7.32 |
| Sep 30, 2022 | -16.82 |
| Jun 30, 2022 | -10.14 |
| Mar 31, 2022 | -10.67 |
| Dec 31, 2021 | -39.58 |
| Sep 30, 2021 | -0.43 |
| Jun 30, 2021 | -0.38 |